Figure 1From: A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritisMean (SD) serum brodalumab concentration × time profiles (semilog) in rheumatoid arthritis patients following (A) repeat subcutaneous administration and (B) repeat intravenous administration. IV, intravenous; SC, subcutaneous.Back to article page